Skip to main content
Log in

Screening study on new tumor marker periplakin for lung cancer

  • Published:
The Chinese-German Journal of Clinical Oncology

Abstract

Objective

The aim of this study was to use lung cancer targeting binding polypeptide ZS-9 to screen cDNA library of human lung cancer and obtain ZS-9 specific ligand to confirm tumor marker of non small-cell lung cancer.

Methods

Artificially synthesize biotin labeled peptide ZS-9, anchored ZS-9 in the enzyme label plate coupled by avidin, used ZS-9 as probe to screen cDNA library of human lung cancer, after screening, obtained bacteriophage clone specifically binding with anchored polypeptide ZS-9. Extracted plasmid of bacteriophage and performed sequencing after amplified by PCR.

Results

It was demonstrated by bioinformatic analysis on the sequence of ligand binded by lung cancer specific peptide ZS-9 that the ligand was the cytoskeletal protein periplakin on the surface of lung cancer cells, suggesting that periplakin might be a new marker for non-small-cell lung cancer in lung cancer.

Conclusion

Use specific lung cancer binding peptide to screen new tumor marker periplakin in lung cancer and further studies on its biologic functions in genesis and development of lung cancer are still needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Wang JY, Shi L, Dai SQ, et al. Screening of lung cancer specif ic peptide ZS-9 from a phage display peptide library and NCI-H1299 cells. Chin J Pathophysiol (Chinese), 2009, 25: 868–872.

    CAS  Google Scholar 

  2. Rougeon F, Mach, B. Stepwise biosynthesis in vitro of globingenes from globin m RN A by DN Apolymerase of avian myeloblastosis virus. Proc Natl Acad Sci USA, 1976, 73: 3418–3422.

    Article  PubMed  CAS  Google Scholar 

  3. Efstratiadis A, Kafatos FC, Maxam AM, et al. Enzymatic invitro synthesis of globin genes. Cell, 1976, 7: 279–288.

    Article  PubMed  CAS  Google Scholar 

  4. Tochitani S, Hayashizaki Y. Functional screening revisited in the postgenomic era. Mol Biosyst, 2007, 3: 195–207.

    Article  PubMed  CAS  Google Scholar 

  5. Jones JO, Diamond MI. Diamond, Design and implementation of cellbased assays to model human disease. ACS Chem Biol, 2007, 2: 718–724.

    Article  PubMed  CAS  Google Scholar 

  6. Yue WT, Wang ZT, Wang Y, et al. Construction and quality identification of T7 recombination expression cDNA library form human lung cancer. Chinese-German J Clin Oncol, 2009, 8: 195–198.

    Article  CAS  Google Scholar 

  7. Song MH, Ha JC, Lee SM, et al. Identification of BCP-20 (FBXO39) as a cancer/testis antigen from colon cancer patients by SEREX. Biochem Biophys Res Commun, 2011, 408: 195–201.

    Article  PubMed  CAS  Google Scholar 

  8. Cooper CD, Lawrie CH, Liggins AP, et al. Identification and characterization of peripheral T-cell lymphoma-associated SEREX antigens. PLoS One, 2011, 6: 23916.

    Article  Google Scholar 

  9. Jager D. Potential target antigens for immunotherapy identified by serological expression cloning (SEREX). Methods Mol Biol, 2007, 360: 319–326.

    PubMed  Google Scholar 

  10. Nishimori T, Tomonaga T, Matsushita K, et al. Proteomic analysis of primary esophageal squamous cellcarcinoma reveals downregulation of a cell adhesion protein, periplakin. Proteomics, 2006, 6, 1011–1018.

    Article  PubMed  CAS  Google Scholar 

  11. Tonoike Y, Matsushita K, Tomonaga T, et al. Adhesion molecule periplakin is involved in cellular movement and attachment in pharyngeal squamous cancer cells. BMC Cell Biology 2011, 12: 41

    Article  PubMed  CAS  Google Scholar 

  12. Sun Q, Wang Y, Zhang Y, et al. Expression profiling reveals dysregulation of cellular cytoskeletal genes in HBx-induced hepatocarcinogenesis. Cancer Biol Ther, 2007. 6: 668–674.

    Article  PubMed  CAS  Google Scholar 

  13. Suzuki A, Horiuchi A, Ashida T, et al. Cyclin A2 confers cisplatin resistance to endometrial carcinoma cells via up-regulation of an Akt-binding protein, periplakin. J Cell Mol Med, 2010, 14: 2305–2317.

    Article  PubMed  CAS  Google Scholar 

  14. Mignogna MD, Fortuna G, Leuci S, et al. Metastatic prostate cancer presenting as paraneoplastic pemphigus: a favourable clinical response to combined androgen blockade and conventional immunosuppressive therapy. Br J Dermatol, 2009, 160: 468–470.

    Article  PubMed  CAS  Google Scholar 

  15. Yokokura H, Demitsu T, Kakurai M, et al. Paraneoplastic pemphigus mimicking erosive mucosal lichen planus associated with primary hepatocellular carcinoma. J Dermatol, 2006, 33: 842–845.

    Article  PubMed  Google Scholar 

  16. Zimmermann J, Bahmer F, Rose C, et al. Clinical and immunopathological spectrum of paraneoplastic pemphigus. J Dtsch Dermatol Ges, 2010, 8: 598–606.

    PubMed  Google Scholar 

  17. Wang J, Zhu X, Li R, et al. Paraneoplastic pemphigus associated with Castleman tumor: a commonly reported subtype of paraneoplastic pemphigus in China. Arch Dermatol, 2005, 141: 1285–1293.

    Article  PubMed  Google Scholar 

  18. Li YM, Liu PH, Zhang YH, et al. Radiotherapy of unicentric mediastinal Castleman’s disease. Chin J Cancer, 2011, 30: 351–356.

    Article  PubMed  Google Scholar 

  19. Kennedy, NA, Dawe S. Atypical paraneoplastic pemphigus secondary to endometrial carcinoma with no mucosal involvement. Clin Exp Dermatol, 2009, 34: 130–133.

    Article  Google Scholar 

  20. Taillé C, Grootenboer-Mignot S, Boursier C, et al. Identification of Periplakin as a New Target for Autoreactivity in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med, 2011, 183: 759–766.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Junye Wang or Linquan Zang.

Additional information

Supported by grants from the Science and Technology Planning Project of Guangdong Province (No. 2010B031600066; No. 2010B031500034; No. 2008B030303008); the Key Scientific Subject Foundation of Ministry of Education of China (No. 208105); and the National Science and Technology Major Projects for New Drugs (No. 2011zx09102-001-31).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dai, S., Li, W., Kong, M. et al. Screening study on new tumor marker periplakin for lung cancer. Chin. -Ger. J. Clin. Oncol. 12, 305–309 (2013). https://doi.org/10.1007/s10330-013-1178-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10330-013-1178-y

Key words

Navigation